Study Stopped
Covid-19 pandemic
Cognition, Pain and Wellbeing
CPW
The Link Between Cognitive Function and Chronic Pain: An Observational Cohort Study
1 other identifier
observational
8
1 country
1
Brief Summary
Osteoarthritis (OA) is the most common form of arthritis and for 4 in 10 people pain from OA is not adequately controlled. The pain experience of people suffering from chronic pain largely depends on their individual perception of pain and on brain functions, in particular what is called "cognitive" functions. Cognitive functions include memory, attention, organisation and planning, task initiation, regulation of emotions and reflection of oneself and are important for everyday tasks, such as following a conversation or a story in a book or on TV, learning new things, remembering old and new information and making decisions. Good cognition predicts the risk of developing chronic pain after a painful event, such as surgery. Chronic pain patients report numerous cognitive impairments, with attention and memory being the two most prominent that can persist even after the original cause of pain has been treated. Little evidence exists regarding the nature and magnitude of these deficits and their underlying brain and psychological mechanisms in chronic knee OA. The investigators want to understand which cognitive functions and to what extent are associated with pain in patients with knee OA.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Nov 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 7, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 20, 2020
CompletedFirst Submitted
Initial submission to the registry
April 22, 2020
CompletedFirst Posted
Study publicly available on registry
November 9, 2020
CompletedMay 8, 2024
May 1, 2024
4 months
April 22, 2020
May 6, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (8)
Pain sensitivity measures
Quantitative sensory testing (QST) will be used to assess pain sensitivity with measures, such as pressure pain threshold (PPT). PPT is a valid measure of tenderness around the knee. QST is used to quantify pain perception and it is an objective measure of peripheral sensitisation (increased tenderness around the knee) and central sensitisation (increased pain perception in areas away from the knee). QST will be used to identify different pain phenotypes among participants and it will enable us to quantify peripheral and central sensitisation components of pain. Pain phenotypes will be then correlated to cognitive measures.
Conducted once, at assessment visit approximately 10 minutes
Pain sensitivity measures
Quantitative sensory testing (QST) will be used to assess pain sensitivity with measures, such as temporal summation (TS), TS is a measure of central sensitization. QST is used to quantify pain perception and it is an objective measure of peripheral sensitisation (increased tenderness around the knee) and central sensitisation (increased pain perception in areas away from the knee). QST will be used to identify different pain phenotypes among participants and it will enable us to quantify peripheral and central sensitisation components of pain. Pain phenotypes will be then correlated to cognitive measures.
Conducted once, at assessment visit approximately 4 minutes
Pain sensitivity measures
Quantitative sensory testing (QST) will be used to assess pain sensitivity with measures, such as conditioned pain modulation (CPM). CPM assesses the function of endogenous pain inhibitory pathways. QST is used to quantify pain perception and it is an objective measure of peripheral sensitisation (increased tenderness around the knee) and central sensitisation (increased pain perception in areas away from the knee). QST will be used to identify different pain phenotypes among participants and it will enable us to quantify peripheral and central sensitisation components of pain. Pain phenotypes will be then correlated to cognitive measures.
Conducted once, at assessment visit approximately 6 minutes
Pain severity measure
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), which is a self-administered 24 items questionnaire with three subscales assessing pain, stiffness and physical function, is an extensively utilised tool for the evaluation of hip and knee OA and will be used in the current study.
Conducted once, at assessment visit : approximately 5-10 minutes
Cognitive function
Cambridge Neuropsychological Test Automated Battery (CANTAB) (objective measure) including tests of prefrontal-dependent sustained visual attention (Rapid Visual Information Processing, RVP, 7 min), attentional set shifting (Intra-/ Extra- Dimensional Set Shift, IED, 7 min) and hippocampus-dependent paired associate learning (Visual Learning Paired Associates Learning, PAL, 8 min) will be used. Other CANTAB tests will be included for comparison (reaction time test, RTI, 3 min; Stroop-like test, MTT, 8 min; spatial working memory test, SWM, 4 min).
Conducted once, at assessment visit : approximately 40 minutes
Cognitive function
Questionnaire cognitive measures, including the Cognitive Failures Questionnaire (CFQ) will be used.
Conducted once, at assessment visit approximately 8 minutes
Cognitive function
Questionnaire cognitive measures including the Cognitive reflection test (CRT) will be used.
Conducted once, at assessment visit approximately 7 minutes
Neuropathic pain quality: PD-Q
The PainDETECT Questionnaire (PD-Q) is a self-report questionnaire developed to discriminate between nociceptive and neuropathic pain. It has been further modified (mPDQ) for use among specific pain groups, for example, knee pain. Neuropathic pain symptoms as identified with the mPDQ have been found to correlate with signs of central sensitisation in OA, as identified with QST.
Conducted once, at assessment visit : approximately 5-10 minutes
Secondary Outcomes (10)
Premorbid IQ
Conducted once, at assessment visit approximately 10-15 minutes
Depression/Anxiety
Conducted once, at assessment visit approximately 5-10 minutes
Sleep Quality: PSQI
Conducted once, at assessment visit approximately 5-10 minutes
Physical function
Conducted once, at assessment visit approximately 6 minutes
Physical function
Conducted once, at assessment visit approximately 5 minutes
- +5 more secondary outcomes
Study Arms (2)
Participants with the relevant condition
Participants with the relevant condition
Healthy controls
Healthy controls
Eligibility Criteria
Participants will be recruited from previous studies undertaken by the Academic Rheumatology, University of Nottingham, who have expressed an interest in future research. Responders from the Investigating Musculoskeletal Health and Wellbeing cohort study (IMHWCS, n \~ 5,000) and Knee Pain and related health In the Community cohort study (KPIC, n \~ 3,000) will be sent an invitation letter and participant information sheet (PIS) with details about the Cognition, Pain and Wellbeing study. A telephone screening will be then done to confirm their eligibility for the study and their interest in participating and they will be booked an appointment for a single visit in Academic Rheumatology.
You may qualify if:
- Aged 40 years and onward
- Able to read and write English
- Have English as their first language
You may not qualify if:
- Persons who do not adequately understand verbal explanations of written information in English, or who have special communication needs or whose English is not their first language
- Dialysis patients or on home oxygen
- Terminal illness
- Serious mental illness
- Dementia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Nottingham
Nottingham, United Kingdom
Biospecimen
Whole blood (20ml), urine and faecal samples will be retained to identify inflammatory biomarkers, biomarkers of insulin resistance and gut microbiome measures.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ana M Valdes, PhD
University of Nottingham
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
April 22, 2020
First Posted
November 9, 2020
Study Start
November 7, 2019
Primary Completion
March 20, 2020
Study Completion
March 20, 2020
Last Updated
May 8, 2024
Record last verified: 2024-05